CN103893153A - Venlafaxine hydrochloride sustained-release capsule and preparation method of venlafaxine hydrochloride sustained-release capsule - Google Patents
Venlafaxine hydrochloride sustained-release capsule and preparation method of venlafaxine hydrochloride sustained-release capsule Download PDFInfo
- Publication number
- CN103893153A CN103893153A CN201410155004.7A CN201410155004A CN103893153A CN 103893153 A CN103893153 A CN 103893153A CN 201410155004 A CN201410155004 A CN 201410155004A CN 103893153 A CN103893153 A CN 103893153A
- Authority
- CN
- China
- Prior art keywords
- venlafaxine
- chitosan
- hydrochloride sustained
- release
- venlafaxine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a venlafaxine hydrochloride sustained-release capsule and a preparation method of the venlafaxine hydrochloride sustained-release capsule, belonging to the technical field of medicines. The venlafaxine hydrochloride sustained-release capsule disclosed by the invention is composed of a sustained-release content and a capsule shell. The sustained-release content is composed of a medicine-carrying sugar type pharmaceutical pellet core and a sustained-release layer. The venlafaxine hydrochloride sustained-release capsule disclosed by the invention has the characteristics of being convenient to use, high in compliance, little in adverse reaction, steady in blood concentration and good in curative effect.
Description
Technical field
The present invention relates to a kind of capsule and preparation method thereof, relate in particular to a kind of venlafaxine hydrochloride sustained-release capsule and preparation method thereof, belong to medical technical field.
Background technology
VENLAFAXINE HCL is the antidepressants of new generation of Wyeth-Ayerst company exploitation, and within 1993, December obtains FDA approval on the 28th.VENLAFAXINE HCL is a kind of novel antidepressant that is different from the unique chemical constitution of having of other antidepressants and neuro pharmacology effect, bring into play antidepressant effect by the picked-up again that suppresses 5-hydroxy tryptamine and norepinephrine, to unrestraint effects such as monoamine oxidase, MAO.Because clinical demand is vigorous, FDA ratified venlafaxine hydrochloride sustained-release capsule (trade name: Efexor XR, the Effexor XR) listing of Hui Shi again on October 20th, 1997.From the granted listing of venlafaxine, this kind becomes the core product of Hui Shi, and 1,000,000,000 dollars of high pointes are climbed up rapidly in a year sale, and the rate of increase of every annual sales amount is all more than double figures, the global marketing of 2005 has reached 3,500,000,000 dollars, becomes the antidepressant drug of global sales first.
The Efexor XR of existing market sale is divided into often to be released and two kinds of dosage forms of slow release, and owing to only needing every day slow release formulation to be once more conducive to clinically taking of depressed patient, since listing, the sales volume of slow releasing agent is better than always and often releases agent." the depressive disorder treatment practice guideline " that APA,American Psychiatric Association (APA) published in October, 2010, the recommendation medicine for the treatment of as old, common sick personality disorder etc. venlafaxine sustained-release capsule as special clinical problem especially.
In China market, the venlafaxine that domestic enterprise produces is take normal release dosage form as main, therefore, need to be on former basis of grinding slow release formulation, research and develop new slow release method, to realize the production domesticization of venlafaxine hydrochloride sustained-release dosage form, allow vast domestic patient use venlafaxine hydrochloride sustained-release dosage form of high quality and at a reasonable price.
Summary of the invention
Technical problem to be solved by this invention is that the defect that overcomes prior art provides venlafaxine hydrochloride sustained-release capsule, and this slow releasing capsule has and discharges steadily, release time long, stability advantages of higher.
Technical problem of the present invention is realized by following technical scheme.
A kind of venlafaxine hydrochloride sustained-release capsule, formed by slow release content and capsule shells, described slow release content is made up of medicine carrying cane sugar type medicinal fine pellet core and slow release layer, the component that described medicine carrying cane sugar type medicinal fine pellet core contains following weight portion: VENLAFAXINE HCL is in venlafaxine 120～180, the blank cane sugar type medicinal fine pellet heart 50～60, hypromellose-E51～1.5; The component that described slow release layer contains following weight portion: chitosan-isoborneol conjugate 35～45, stearic acid Nitranitol 5～10 ethanol 140～150, purified water 60～70.
Preferably, above-mentioned venlafaxine hydrochloride sustained-release capsule, the component that described medicine carrying cane sugar type medicinal fine pellet core contains following weight portion: VENLAFAXINE HCL is in venlafaxine 150, blank cane sugar type medicinal fine pellet core 55, hypromellose-E51.3; The component that described slow release layer contains following weight portion: chitosan-isoborneol conjugate 40, stearic acid Nitranitol 8, ethanol 145, purified water 65.
Venlafaxine hydrochloride sustained-release capsule of the present invention is used in treatment all kinds depressions (comprising the depression with anxiety) and generalized anxiety disorder.In the morning or relatively-stationary time in night and food take simultaneously, once a day.Capsule is taken after avoiding separating, crush, chew or dissolving under should overallly taking, and also can carefully open capsule content is put in one spoonful of apple sauce, and the mixture of this medicine/food should not chewed very soon and swallow, under then guaranteeing to take completely with one glass of water.
The preparation method that the present invention further provides above-mentioned venlafaxine hydrochloride sustained-release capsule, comprises the steps:
(1) the VENLAFAXINE HCL raw material pulverizing that takes recipe quantity is extremely without visible particle and caking;
(2) take the HPMC-E5 of recipe quantity, add purified water to be stirred to dissolving, be made into 2% aqueous solution, obtain binding agent for subsequent use;
(3) the blank cane sugar type fine pellet core that journey is got recipe quantity is placed in centrifugal granulator, opens centrifugal granulator, powder on spray binding agent, after completing, 60 ℃ of oven dryings 5 hours, cross 12 orders, 24 mesh sieves, get the medicine carrying cane sugar type medicinal fine pellet core between 12～24 orders, for subsequent use;
(4) deionized water, sodium hexameta phosphate, chitosan are fully disperseed, make solution, for subsequent use; The volume ml of wherein said deionized water is 30:1 with the ratio of chitosan weight g, and the weight mg of described sodium hexameta phosphate is 0.3:1 with the ratio of chitosan weight g;
(5) solution step (4) being made stirs under logical condition of nitrogen gas, control 20～30 revs/min of rotating speeds, add isoborneol, isoborneol weight g is 3～4:1 with the ratio of chitosan weight g, be warming up to 25 ℃～30 ℃, stir after 0.5h, add azo two isobutyl imidazoline salt hydrochlorates, its weight mg is 0.7:1 with the ratio of chitosan weight g, start to clock, and in 10 minutes, drip wherein N-n-pro-pyl acrylamide, its weight mg is 2.5:1 with the ratio of chitosan weight g, drip rear insulation reaction 1h, question response liquid cooling is final vacuum sucking filtration but, obtain filter cake for subsequent use,
(6) filter cake obtaining to step (5) drips washing with alcohol, obtains chitosan-isoborneol conjugate, for subsequent use;
(7) take the ethanol of recipe quantity, under agitation add the stearic acid Nitranitol of recipe quantity, be uniformly dispersed, without shot-like particle, add the purified water of recipe quantity, stirring and dissolving is even, obtains solution for standby;
(8) to the chitosan-isoborneol conjugate that adds recipe quantity in step (7) gained solution, stirring and dissolving is complete, obtains coating solution for subsequent use;
(9) medicine carrying cane sugar type medicinal fine pellet core is put coating in fluid bed, after completing, and 40 ℃ of oven dryings 12 hours; Cross 12 orders, 24 mesh sieves, the medicine carrying micropill of getting the process coating between 12～24 orders is for subsequent use as content;
(10) get step (9) gained content encapsulated, both venlafaxine hydrochloride sustained-release capsule of the present invention.
In the technology about venlafaxine hydrochloride sustained-release capsule, take hypromellose as binding agent, raw material and microcrystalline Cellulose in certain proportion through extruding, the round as a ball pastille micropill of making, take ethyl cellulose as slow-release material, adding a certain amount of hypromellose is that porogen is made slow-release micro-pill again.And the present invention uses cane sugar type medicinal fine pellet core to be prepared from through bundled slow-releasing layer, provide and the diverse a kind of technical scheme of prior art, especially chitosan-isoborneol the conjugate using in the present invention, it is as a kind of new pharmaceutic adjuvant, there is good slow release effect, and can further improve the therapeutical effect of medicine.The release that venlafaxine hydrochloride sustained-release capsule sample of the present invention can continue in water, reach release time more than 24 hours, especially the sample of embodiment 1, it consists of the component that medicine carrying cane sugar type medicinal fine pellet core contains following weight portion: VENLAFAXINE HCL is in venlafaxine 150, blank cane sugar type medicinal fine pellet core 55, hypromellose-E51.3; The component that described slow release layer contains following weight portion: chitosan-isoborneol conjugate 40, stearic acid Nitranitol 8, ethanol 145, purified water 65, energy sustained release 26 hours, thus be that assurance blood drug level, lasting onset are laid a good foundation; Animal test results shows, the release of the controlled effective ingredient VENLAFAXINE HCL processed of venlafaxine hydrochloride sustained-release capsule of the present invention, has good sustained release performance.In addition, influence factor's test, accelerated test, long-term test results show, under each condition, character, related substance, content and release all do not have significant change, show to use the prepared venlafaxine hydrochloride sustained-release capsule quality of prescription of the present invention, preparation method more stable, thereby can under varying environment, store, use this slow releasing capsule still can bring into play good effectiveness, guarantee therapeutic effect.In a word, that venlafaxine hydrochloride sustained-release capsule of the present invention has is easy to use, compliance is high, and untoward reaction is few, and blood drug level is steady, the feature that therapeutic effect is good.
Accompanying drawing explanation
The variation diagram of the content of Fig. 1 venlafaxine hydrochloride sustained-release capsule of the present invention in local organization
The specific embodiment
Below by the specific embodiment, the invention will be further described, but just for helping to understand the present invention, make professional and technical personnel in the field can realize or use the present invention, the present invention do not formed to any restriction.
The preparation of embodiment 1 venlafaxine hydrochloride sustained-release capsule
Content prescription
Medicine carrying cane sugar type medicinal fine pellet core: VENLAFAXINE HCL is in venlafaxine 150g, blank cane sugar type medicinal fine pellet heart 55g, hypromellose-E51.3g;
Slow release layer: chitosan-isoborneol conjugate 40g, stearic acid Nitranitol 8g, ethanol 145g, purified water 65g.
Preparation method:
(1) the VENLAFAXINE HCL raw material pulverizing that takes recipe quantity is extremely without visible particle and caking;
(2) take the HPMC-E5 of recipe quantity, add purified water to be stirred to dissolving, be made into mass concentration and be 2% aqueous solution, obtain binding agent for subsequent use;
(3) the blank cane sugar type fine pellet core that journey is got recipe quantity is placed in centrifugal granulator, opens centrifugal granulator, powder on spray binding agent, after completing, 60 ℃ of oven dryings 5 hours, cross 12 orders, 24 mesh sieves, get the medicine carrying cane sugar type medicinal fine pellet core between 12～24 orders, for subsequent use;
(4) deionized water 3000ml, sodium hexameta phosphate 30mg, chitosan 100g are fully disperseed, make solution, for subsequent use;
(5) solution step (4) being made stirs under logical condition of nitrogen gas, control 25 revs/min of rotating speeds, add isoborneol 350g, be warming up to 25 ℃～30 ℃, stir after 0.5h, add azo two isobutyl imidazoline salt hydrochlorate 70mg, start to clock, and in 10 minutes, drip wherein N-n-pro-pyl acrylamide 250mg, drip rear insulation reaction 1h, question response liquid cooling is final vacuum sucking filtration but, obtains filter cake for subsequent use;
(6) filter cake obtaining to step (5) drips washing with alcohol, and chitosan-isoborneol conjugate 156g, for subsequent use; Chitosan-isoborneol conjugate structural identification:
1. elementary analysis
Table 1 results of elemental analyses
| Element | C（％） | H（％） | N（％） |
| Test value | 61.38 | 8.67 | 4.51 |
| Theoretical value | 61.44 | 8.62 | 4.47 |
Measured value and value of calculation comparison, all in allowable error.
2. ultra-violet absorption spectrum
Get this product, accurately weighed, make 2% solution with dilute hydrochloric acid dilution, at 200-400nm wavelength, place is scanned, and result without absorbing, proves that compound is without conjugated system more than 230nm.
3. mass spectrum (MS)
A. adopt BIFLEX III type MALDI TOF mass spectrograph (Bruker company); Nitrogen laser, wavelength 337nm, adopts ion to postpone to draw the working method of (delayed extraction) and reflection (reflectorn), and cation detects; Take DHB (DHB) as substrate, adopt secondary crystallization method to carry out sample preparation.
Known: the molecule that sample has various different polymerization degrees by molecular weight from 600 to 4400 left and right is formed, the maximum molecular weight that can detect is 4422.4, and quasi-molecular ions presents more regular normal distribution, and peak value increases progressively with 313Da, match with this product monomer mass number 313.The peak of relative abundance maximum is 1292 fragment ion peak, [M+Na]+peak when it is N=4; Near this external m/z1292, also has [M+K]+peak that m/z is 1318.
B. get this product, add dilute sulfuric acid, reflux 5 hours, gained hydrolyzate adopts triple level Four bar mass spectrographs to analyze, and cation detects.Known:
M/Z=332, is [M+H]
+quasi-molecular ions;
M/Z=313 is slough-H of compound
2o fragment ion;
M/Z=160, is [M+H]
+slough-H of peak
2o and R side chain fragment ion
M/Z=155 is the R side chain fragment ion of sloughing.
4. proton nmr spectra (
1hNMR)
Adopt high resolution NMR instrument, take deuterated acetic acid as solvent, mensuration this product and glucosamine reference substance and isoborneol reference substance
1hNMR spectrum, by comparison this product and reference substance
1hNMR spectrogram, finds that the ownership at each peak is almost consistent.
5. carbon-13 nmr spectra (
13cNMR)
Adopt high resolution NMR instrument, take deuterated acetic acid as solvent, mensuration this product and glucosamine reference substance and isoborneol reference substance
13cNMR spectrum, by comparison this product and reference substance
13cNMR spectrogram, finds that the ownership at each peak is almost consistent.
(7) take the ethanol of recipe quantity, under agitation add the stearic acid Nitranitol of recipe quantity, be uniformly dispersed, without shot-like particle, add the purified water of recipe quantity, stirring and dissolving is even, obtains solution for standby;
(8) to the chitosan-isoborneol conjugate that adds recipe quantity in step (7) gained solution, stirring and dissolving is complete, obtains coating solution for subsequent use;
(9) medicine carrying cane sugar type medicinal fine pellet core is put coating in fluid bed, after completing, and 40 ℃ of oven dryings 12 hours; Cross 12 orders, 24 mesh sieves, the medicine carrying micropill of getting the process coating between 12～24 orders is for subsequent use as content;
(10) get step (9) gained content encapsulated, its specification is 150mg/ grain, or 75mg/ grain, both venlafaxine hydrochloride sustained-release capsule of the present invention.
The preparation of embodiment 2 venlafaxine hydrochloride sustained-release capsules
Content prescription
Medicine carrying cane sugar type medicinal fine pellet core: VENLAFAXINE HCL is in venlafaxine 120g, blank cane sugar type medicinal fine pellet heart 50g, hypromellose-E51g;
Slow release layer: chitosan-isoborneol conjugate 35g, stearic acid Nitranitol 5g, ethanol 140g, purified water 60g.
Preparation method is with embodiment 1:
The preparation of embodiment 3 venlafaxine hydrochloride sustained-release capsules
Content prescription
VENLAFAXINE HCL is in venlafaxine 180g, blank cane sugar type medicinal fine pellet heart 60g, hypromellose-E51.5g;
Slow release layer: chitosan-isoborneol conjugate 45g, stearic acid Nitranitol 10g, ethanol 150g, purified water 70g.
Preparation method is with embodiment 1:
The release test of the prepared venlafaxine hydrochloride sustained-release capsule sample of embodiment 4 embodiment 1 to 3 in water adopts 2010 editions dissolution method first method devices of Chinese Pharmacopoeia, take water 900ml as solvent, rotating speed is 100rpm per minute, after corresponding point in time sampling, measure trap according to spectrophotometer at 274nm place, calculate burst size.
Table 2 embodiment 1 to 3 release test result in water
| ? | Embodiment 1(%) | Embodiment 2(%) | Embodiment 3(%) |
| 30min | 3.9 | 7.6 | 2.3 |
| 60min | 11.6 | 12.1 | 5.9 |
| 90min | 15.2 | 17.6 | 11.3 |
| 120min | 21.3 | 23.4 | 18.1 |
| 3 hours | 33.1 | 34.2 | 31.8 |
| 4 hours | 46.4 | 44.2 | 45.7 |
| 5 hours | 55.1 | 51.4 | 53.3 |
| 6 hours | 62.5 | 61.2 | 63.3 |
| 8 hours | 69.6 | 67.6 | 70.6 |
| 10 hours | 74.1 | 72.2 | 75.5 |
| 12 hours | 79.1 | 77.4 | 79.2 |
| 14 hours | 84.3 | 82.4 | 85.2 |
| 16 hours | 88.2 | 85.5 | 96.0 |
| 18 hours | 89.4 | 89.2 | 97.5 |
| 20 hours | 90.4 | 92.2 | 99.1 |
| 24 hours | 92.7 | 98.5 | 101.5 |
| 26 hours | 98.7 | 99.1 | —— |
As can be seen here, the release that the prepared venlafaxine hydrochloride sustained-release capsule sample of embodiment 1 to 3 can continue in water, reach release time more than 24 hours, the especially sample energy sustained release 26 hours of embodiment 1, thereby for guaranteeing blood drug level, continue onset and lay a good foundation.
Embodiment 5 venlafaxine hydrochloride sustained-release capsule of the present invention animal in-vivo content determination
(1) prepared venlafaxine hydrochloride sustained-release capsule, the commercially available venlafaxine hydrochloride sustained-release capsule of embodiment 1
(2) test animal:
72 of rat (body weight 250-260g/ only);
(3) method of testing:
1, rat is divided into two groups, 36 every group, A group gives the prepared venlafaxine hydrochloride sustained-release capsule of embodiment 1; B group gives commercially available venlafaxine hydrochloride sustained-release capsule;
2, measure respectively the content of VENLAFAXINE HCL in oral rear 12h, 24h, 36h.
(4) result:
1, A group still reaches 11～14ug/g at oral rear the 2nd day topical remedy's content;
2, B group has not detected VENLAFAXINE HCL in tissue in oral latter the 2nd day;
Fig. 1 shows that in local organization, effective ingredient VENLAFAXINE HCL can remain to the 2nd day.
Result shows, the release of the controlled effective ingredient VENLAFAXINE HCL processed of the prepared venlafaxine hydrochloride sustained-release capsule of the present invention,
There is good sustained release performance.
The stability experiment of embodiment 6 venlafaxine hydrochloride sustained-release capsule of the present invention
(1) influence factor's test
Get the prepared sour venlafaxine sustained-release capsule of embodiment 1, specification: 150mg, aluminium-plastic bubble plate packing, has carried out respectively testing under high temperature, high humidity, illumination condition.
Table 3 venlafaxine hydrochloride sustained-release capsule influence factor result
(2) accelerated test
Get the prepared sour venlafaxine sustained-release capsule of embodiment 1, specification: 150mg, aluminium-plastic bubble plate packing, investigation condition: 40 ℃ ± 2 ℃ 75% ± 5%RH.
Table 4 venlafaxine hydrochloride sustained-release capsule accelerated test result
(3) long term test
Get the prepared sour venlafaxine sustained-release capsule of embodiment 1, specification: 150mg, aluminium-plastic bubble plate packing, investigation condition: 25 ℃ ± 2 ℃ 60 ± 10%RH.
Table 5 venlafaxine hydrochloride sustained-release capsule long-term test results
(4) study on the stability result
The prepared venlafaxine hydrochloride sustained-release capsule of embodiment 1 is placed 10 days, compared with 0 day, under each condition, character, related substance, content and release all do not have significant change, show to use the prepared venlafaxine hydrochloride sustained-release capsule quality of prescription of the present invention, preparation method more stable.In addition, accelerated test and long-term test results show, this venlafaxine hydrochloride sustained-release capsule indices of the present invention has no significant change, all meets quality standard regulation, and visible this product has good stability.As seen from the experiment, venlafaxine hydrochloride sustained-release capsule of the present invention has good stability, thereby can under varying environment, store, use this slow releasing capsule still can bring into play good effectiveness, assurance therapeutic effect.
Above-described embodiment is only explanation technical conceive of the present invention and advantage; the present invention also can have other variation; as well known to the skilled person; above-described embodiment only plays the exemplary role in foregoing invention protection domain; for those of ordinary skills; in the protection domain limiting in the present invention, also have a lot of conventional distortion and other embodiment, these distortion and embodiment are by within the protection domain awaiting the reply in the present invention.
Claims (3)
1. a venlafaxine hydrochloride sustained-release capsule, formed by slow release content and capsule shells, described slow release content is made up of medicine carrying cane sugar type medicinal fine pellet core and slow release layer, it is characterized in that, the component that described medicine carrying cane sugar type medicinal fine pellet core contains following weight portion: VENLAFAXINE HCL is in venlafaxine 120～180, the blank cane sugar type medicinal fine pellet heart 50～60, hypromellose-E51～1.5; The component that described slow release layer contains following weight portion: chitosan-isoborneol conjugate 35～45, stearic acid Nitranitol 5～10, ethanol 140～150, purified water 60～70.
2. venlafaxine hydrochloride sustained-release capsule according to claim 1, it is characterized in that the component that described medicine carrying cane sugar type medicinal fine pellet core contains following weight portion: VENLAFAXINE HCL is in venlafaxine 150, blank cane sugar type medicinal fine pellet core 55, hypromellose-E51.3; The component that described slow release layer contains following weight portion: chitosan-isoborneol conjugate 40, stearic acid Nitranitol 8, ethanol 145, purified water 65.
3. a method of preparing venlafaxine hydrochloride sustained-release capsule as claimed in claim 1 or 2, is characterized in that, comprises the steps:
(1) the VENLAFAXINE HCL raw material pulverizing that takes recipe quantity is extremely without visible particle and caking;
(2) take the HPMC-E5 of recipe quantity, add purified water to be stirred to dissolving, be made into 2% aqueous solution, obtain binding agent for subsequent use;
(3) the blank cane sugar type fine pellet core that journey is got recipe quantity is placed in centrifugal granulator, opens centrifugal granulator, powder on spray binding agent, after completing, 60 ℃ of oven dryings 5 hours, cross 12 orders, 24 mesh sieves, get the medicine carrying cane sugar type medicinal fine pellet core between 12～24 orders, for subsequent use;
(4) deionized water, sodium hexameta phosphate, chitosan are fully disperseed, make solution, for subsequent use; The volume ml of wherein said deionized water is 30:1 with the ratio of chitosan weight g, and the weight mg of described sodium hexameta phosphate is 0.3:1 with the ratio of chitosan weight g;
(5) solution step (4) being made stirs under logical condition of nitrogen gas, control 20～30 revs/min of rotating speeds, add isoborneol, isoborneol weight g is 3～4:1 with the ratio of chitosan weight g, be warming up to 25 ℃～30 ℃, stir after 0.5h, add azo two isobutyl imidazoline salt hydrochlorates, its weight mg is 0.7:1 with the ratio of chitosan weight g, start to clock, and in 10 minutes, drip wherein N-n-pro-pyl acrylamide, its weight mg is 2.5:1 with the ratio of chitosan weight g, drip rear insulation reaction 1h, question response liquid cooling is final vacuum sucking filtration but, obtain filter cake for subsequent use,
(6) filter cake obtaining to step (5) drips washing with alcohol, obtains chitosan-isoborneol conjugate, for subsequent use;
(7) take the ethanol of recipe quantity, under agitation add the stearic acid Nitranitol of recipe quantity, be uniformly dispersed, without shot-like particle, add the purified water of recipe quantity, stirring and dissolving is even, obtains solution for standby;
(8) to the chitosan-isoborneol conjugate that adds recipe quantity in step (7) gained solution, stirring and dissolving is complete, obtains coating solution for subsequent use;
(9) medicine carrying cane sugar type medicinal fine pellet core is put coating in fluid bed, after completing, and 40 ℃ of oven dryings 12 hours; Cross 12 orders, 24 mesh sieves, the medicine carrying micropill of getting the process coating between 12～24 orders is for subsequent use as content;
(10) get step (9) gained content encapsulated, both venlafaxine hydrochloride sustained-release capsule of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410155004.7A CN103893153B (en) | 2014-04-17 | 2014-04-17 | A kind of venlafaxine hydrochloride slow-release capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410155004.7A CN103893153B (en) | 2014-04-17 | 2014-04-17 | A kind of venlafaxine hydrochloride slow-release capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103893153A true CN103893153A (en) | 2014-07-02 |
| CN103893153B CN103893153B (en) | 2016-04-13 |
Family
ID=50984947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410155004.7A Active CN103893153B (en) | 2014-04-17 | 2014-04-17 | A kind of venlafaxine hydrochloride slow-release capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893153B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784222A (en) * | 2015-05-21 | 2015-07-22 | 张春燕 | Pharmaceutical preparation containing ginkgo biloba extract and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050106248A1 (en) * | 2003-11-17 | 2005-05-19 | Manesh Dixit | Extended release venlafaxine formulation |
| WO2010066159A1 (en) * | 2008-12-10 | 2010-06-17 | 上海复星普适医药科技有限公司 | A preparation method of venlafaxine sustained release formulation |
| CN101987091A (en) * | 2009-08-07 | 2011-03-23 | 北京天衡药物研究院 | Venlafaxine hydrochloride sustained-release pellet capsules |
| CN102406619A (en) * | 2011-11-29 | 2012-04-11 | 北京科信必成医药科技发展有限公司 | Sustained release pellet and preparation method thereof |
| CN102429873A (en) * | 2011-11-29 | 2012-05-02 | 北京科信必成医药科技发展有限公司 | Desmethylvenlafaxine sustained-release pellet and preparation method thereof |
| CN102935071A (en) * | 2012-11-29 | 2013-02-20 | 青岛黄海制药有限责任公司 | Venlafaxine hydrochloride controlled-release pellet and preparation method thereof |
| CN103211791A (en) * | 2012-01-18 | 2013-07-24 | 北京天衡药物研究院 | Venlafaxine hydrochloride film-controlled slow-release pellet capsule |
-
2014
- 2014-04-17 CN CN201410155004.7A patent/CN103893153B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050106248A1 (en) * | 2003-11-17 | 2005-05-19 | Manesh Dixit | Extended release venlafaxine formulation |
| WO2010066159A1 (en) * | 2008-12-10 | 2010-06-17 | 上海复星普适医药科技有限公司 | A preparation method of venlafaxine sustained release formulation |
| CN101987091A (en) * | 2009-08-07 | 2011-03-23 | 北京天衡药物研究院 | Venlafaxine hydrochloride sustained-release pellet capsules |
| CN102406619A (en) * | 2011-11-29 | 2012-04-11 | 北京科信必成医药科技发展有限公司 | Sustained release pellet and preparation method thereof |
| CN102429873A (en) * | 2011-11-29 | 2012-05-02 | 北京科信必成医药科技发展有限公司 | Desmethylvenlafaxine sustained-release pellet and preparation method thereof |
| CN103211791A (en) * | 2012-01-18 | 2013-07-24 | 北京天衡药物研究院 | Venlafaxine hydrochloride film-controlled slow-release pellet capsule |
| CN102935071A (en) * | 2012-11-29 | 2013-02-20 | 青岛黄海制药有限责任公司 | Venlafaxine hydrochloride controlled-release pellet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784222A (en) * | 2015-05-21 | 2015-07-22 | 张春燕 | Pharmaceutical preparation containing ginkgo biloba extract and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103893153B (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108884019A (en) | Deuterated chloramines ketone derivatives | |
| EP3711767A1 (en) | Pharmaceutical preparation having excellent photostability and drug release properties | |
| AU2011220206B2 (en) | Capsule of compound danshen dripping pills | |
| CN108272765A (en) | Pharmaceutical composition, oral disintegrating tablet and its preparation, the application of hydrochloric Vardenafil | |
| CN103768063B (en) | A kind of moxifloxacin hydrochloride medicinal composition and preparation method thereof | |
| CN101653425B (en) | Arbidol hydrochloride medicament composition dispersible tablets and preparation method thereof | |
| CN103893153B (en) | A kind of venlafaxine hydrochloride slow-release capsule and preparation method thereof | |
| CN112370420A (en) | Medicinal gel and preparation method and application thereof | |
| CN102429912B (en) | Pharmaceutical composition prepared with micronized prasterone or sodium prasterone sulfate and use thereof | |
| CN105030716B (en) | Caffeinum pharmaceutical combination and preparation method thereof | |
| CN104447770A (en) | Asenapine compound | |
| CN110693860A (en) | Gel plaster containing ketoprofen and preparation method thereof | |
| JPS609697B2 (en) | formulation | |
| CN112386578B (en) | Montelukast sodium chewable tablet and preparation method thereof | |
| CN104276960B (en) | Tapentadol hydrochloride and celecoxib eutectic and combinations thereof thing and preparation method | |
| CN105395518A (en) | Clonidine hydrochloride sustained-release capsule | |
| CN102836144A (en) | Deoxidized epinephrine oral instant film and preparation method thereof | |
| CN111067883A (en) | Preparation method of terbinafine hydrochloride liniment | |
| CN106632031A (en) | Dequalinium chloride crystal and buccal tablet thereof, and preparation method of buccal tablet | |
| CN106727371B (en) | Donepezil hydrochloride pharmaceutical composition and preparation method thereof | |
| US20220387477A1 (en) | Pharmaceutical compositions containing alginate oligosaccharaide diacid | |
| CN108553416A (en) | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride | |
| CN103315983A (en) | Rasagiline preparation and preparation method thereof | |
| CN105250240B (en) | Oral sustained-release preparation containing hydrocodone and chlorpheniramine | |
| CN101947205B (en) | Novel galanthamine sustained-release preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |